MA34094B1 - Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 - Google Patents

Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2

Info

Publication number
MA34094B1
MA34094B1 MA35260A MA35260A MA34094B1 MA 34094 B1 MA34094 B1 MA 34094B1 MA 35260 A MA35260 A MA 35260A MA 35260 A MA35260 A MA 35260A MA 34094 B1 MA34094 B1 MA 34094B1
Authority
MA
Morocco
Prior art keywords
prostaglandin
tetrahydro
receptor
modulators
heteroarylamino
Prior art date
Application number
MA35260A
Other languages
Arabic (ar)
English (en)
Inventor
Hamed Aissaoui
Heinz Fretz
Julien Hazemann
Sylvia Richard-Bildstein
Romain Siegrist
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA34094B1 publication Critical patent/MA34094B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne des dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole représentés par la formule (i), dans laquelle r1, r2 et r3 sont tels que décrits dans la description, ainsi que leur utilisation comme modulateurs de récepteurs de prostaglandine, plus particulièrement comme modulateurs du récepteur de la prostaglandine d2, dans le traitement de diverses maladies et divers troubles à médiation par la prostaglandine. L'invention concerne également des compositions pharmaceutiques contenant ces composés et des procédés pour leur préparation.
MA35260A 2010-03-22 2011-03-21 Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 MA34094B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2010051228 2010-03-22
PCT/IB2011/051165 WO2011117798A1 (fr) 2010-03-22 2011-03-21 Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2

Publications (1)

Publication Number Publication Date
MA34094B1 true MA34094B1 (fr) 2013-03-05

Family

ID=43929122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35260A MA34094B1 (fr) 2010-03-22 2011-03-21 Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2

Country Status (28)

Country Link
US (1) US8697869B2 (fr)
EP (1) EP2558447B1 (fr)
JP (1) JP5291265B2 (fr)
KR (1) KR101444572B1 (fr)
CN (1) CN102791689B (fr)
AR (1) AR080703A1 (fr)
AU (1) AU2011231208B2 (fr)
BR (1) BR112012024114B1 (fr)
CA (1) CA2790139C (fr)
CL (1) CL2012002570A1 (fr)
CY (1) CY1115800T1 (fr)
DK (1) DK2558447T3 (fr)
ES (1) ES2524079T3 (fr)
HR (1) HRP20141208T1 (fr)
IL (1) IL221977A (fr)
MA (1) MA34094B1 (fr)
MX (1) MX2012010820A (fr)
MY (1) MY183111A (fr)
NZ (1) NZ603108A (fr)
PH (1) PH12012501863A1 (fr)
PL (1) PL2558447T3 (fr)
PT (1) PT2558447E (fr)
RU (1) RU2562255C2 (fr)
SG (1) SG183835A1 (fr)
SI (1) SI2558447T1 (fr)
TW (1) TWI562987B (fr)
WO (1) WO2011117798A1 (fr)
ZA (1) ZA201207894B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5964945B2 (ja) * 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用
CN103450218B (zh) * 2012-05-29 2015-12-23 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类三并环衍生物
WO2014066568A1 (fr) 2012-10-24 2014-05-01 Winthrop-University Hospital Biomarqueur non invasif permettant d'identifier des sujets risquant un accouchement avant terme
JP6479818B2 (ja) * 2013-05-10 2019-03-06 シーエヌアイシー ファンデーション セントロ ナショナル デ インベスティゲイショネス カーディオバスキュレアス カルロス ザ サード 骨髄増殖性新生物の治療に適した化合物
CA2939892C (fr) * 2014-03-17 2020-03-31 Idorsia Pharmaceuticals Ltd Derives d'acide aza-indol-acetique et leur utilisation comme modulateurs des recepteurs de la prostaglandine d2
CN106103437A (zh) * 2014-03-18 2016-11-09 埃科特莱茵药品有限公司 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
CN108026093B (zh) * 2015-09-15 2021-11-16 爱杜西亚药品有限公司 结晶形式
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
CN113995758B (zh) * 2021-11-04 2023-06-02 中山大学 咔唑-嘧啶衍生物在制备治疗抗肿瘤药物中的应用
WO2025038666A2 (fr) * 2023-08-13 2025-02-20 GATC Health Corp Composés et méthodes de traitement de la dépendance

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
ID23053A (id) * 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
ATE311200T1 (de) 2000-04-12 2005-12-15 Merck Frosst Canada Inc Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
ATE340796T1 (de) 2001-05-23 2006-10-15 Merck Frosst Canada Inc Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
WO2003051837A2 (fr) 2001-12-14 2003-06-26 Zentaris Gmbh Derives tetrahydrocarbazol servant de ligands de recepteurs couples aux proteines g (gpcr)
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003097042A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
WO2003097598A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Composé comprenant un antagonisme du récepteur de pdg2
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
BR0315681A (pt) 2002-10-30 2005-09-06 Merck Frosst Canada Inc Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável
JPWO2004078719A1 (ja) 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
EP1631547A1 (fr) 2003-05-20 2006-03-08 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl- cycloalkanoindoles substitues et leur utilisation en tant qu'antagonistes de prostaglandine d2
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2004111047A2 (fr) 2003-06-12 2004-12-23 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines utilisees comme antagonistes du recepteur dp
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005033099A2 (fr) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
JP2007508363A (ja) 2003-10-14 2007-04-05 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
WO2005040112A1 (fr) 2003-10-14 2005-05-06 Oxagen Limited Composes a activite antagoniste de pgd2
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2005073234A2 (fr) 2004-01-31 2005-08-11 Actimis Pharmaceuticals, Inc. Derives d'acide imidazo[1,2-c]pyrimidinylacetique
AU2005229522A1 (en) 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd. Indol-1-yl-acetic acid derivatives
US7714132B2 (en) * 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
FR2869878B1 (fr) 2004-05-04 2006-08-04 Mecan Outil Sa Sa Procede et dispositif d'emballage d'objets allonges fragiles
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
WO2006034418A2 (fr) 2004-09-21 2006-03-30 Athersys, Inc. Acides benzimidazole acetiques presentant un antagonisme du recepteur crth2 et utilisations associees
JP2008513512A (ja) 2004-09-21 2008-05-01 アサーシス， インク． Ｃｒｔｈ２受容体拮抗作用を示すインドール酢酸およびこれらの使用
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
ES2369782T3 (es) 2004-12-27 2011-12-05 Actelion Pharmaceuticals Ltd. Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2.
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422829A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422830A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
JP5024039B2 (ja) 2005-02-25 2012-09-12 小野薬品工業株式会社 インドール化合物およびその用途
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
KR101333861B1 (ko) 2005-05-24 2013-11-28 메르크 세로노 에스. 에이. Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
US7956082B2 (en) 2005-07-22 2011-06-07 Shionogi & Co., Ltd Indole derivative having PGD2 receptor antagonist activity
AU2006281937B2 (en) 2005-08-12 2011-11-17 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US20070203209A1 (en) 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
EP1932839A4 (fr) 2005-09-06 2014-09-10 Shionogi & Co Dérivé d acide indolécarboxylate ayant une activité à effet antagoniste du récepteur pgd2
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525141D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
WO2008012511A1 (fr) 2006-07-22 2008-01-31 Oxagen Limited Composés présentant une activité d'antagonistes crth2
AU2007276885A1 (en) 2006-07-25 2008-01-31 Sanofi-Aventis 2-phenyl-indoles as prostaglandin D2 receptor antagonists
MY147588A (en) 2006-08-07 2012-12-31 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
EP2094266A1 (fr) 2006-12-21 2009-09-02 Argenta Discovery Limited Antagonistes de crth2
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
US20100137300A1 (en) 2007-03-21 2010-06-03 George Hynd Indolizine Acetic Acid Derivatives as CRTH2 Antagonists
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
GB0719485D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
WO2009049021A1 (fr) 2007-10-10 2009-04-16 Chemietek, Llc Composés hétérocycliques sous forme d'antagonistes du récepteur crth2
WO2009061676A2 (fr) 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonistes de récepteurs pgd2
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
NZ585888A (en) 2007-12-14 2012-02-24 Pulmagen Therapeutics Asthma Ltd Indoles and their therapeutic use
RS53142B (sr) 2008-01-18 2014-06-30 Atopix Therapeutics Limited Jedinjenja koja imaju antagonističku aktivnost na crth2
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US20110060026A1 (en) 2008-01-18 2011-03-10 George Hynd Indoles Active on CRTH2 Receptor
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
US20100022613A1 (en) 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
JP2011088826A (ja) 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
JP2011526281A (ja) 2008-06-24 2011-10-06 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
EP2307382B1 (fr) 2008-07-15 2011-12-21 F. Hoffmann-La Roche AG Acides aminotétrahydroindazoloacétiques
JP5394488B2 (ja) 2008-07-15 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー アミノテトラヒドロインダゾロ酢酸
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US8637671B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
AU2009295231A1 (en) 2008-09-22 2010-03-25 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
US20110312945A1 (en) 2008-10-01 2011-12-22 James Jia Crth2 modulators
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US20110311483A1 (en) 2010-03-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用

Also Published As

Publication number Publication date
CL2012002570A1 (es) 2012-12-21
US8697869B2 (en) 2014-04-15
EP2558447A1 (fr) 2013-02-20
CN102791689A (zh) 2012-11-21
CN102791689B (zh) 2014-10-29
HRP20141208T1 (hr) 2015-02-13
DK2558447T3 (da) 2014-11-10
WO2011117798A1 (fr) 2011-09-29
IL221977A (en) 2014-09-30
KR101444572B1 (ko) 2014-09-24
CA2790139A1 (fr) 2011-09-29
RU2012144543A (ru) 2014-04-27
BR112012024114A2 (pt) 2018-05-08
MX2012010820A (es) 2012-10-10
PT2558447E (pt) 2014-11-25
HK1181048A1 (en) 2013-11-01
AR080703A1 (es) 2012-05-02
AU2011231208A1 (en) 2012-11-08
AU2011231208B2 (en) 2015-03-26
BR112012024114B1 (pt) 2021-02-09
IL221977A0 (en) 2012-12-02
MY183111A (en) 2021-02-15
KR20130004922A (ko) 2013-01-14
PL2558447T3 (pl) 2015-03-31
JP2013522355A (ja) 2013-06-13
SI2558447T1 (sl) 2015-01-30
ES2524079T3 (es) 2014-12-04
TW201139373A (en) 2011-11-16
US20130065902A1 (en) 2013-03-14
CA2790139C (fr) 2018-03-13
SG183835A1 (en) 2012-10-30
PH12012501863A1 (en) 2021-06-23
EP2558447B1 (fr) 2014-09-17
ZA201207894B (en) 2014-03-26
RU2562255C2 (ru) 2015-09-10
JP5291265B2 (ja) 2013-09-18
CY1115800T1 (el) 2017-01-25
NZ603108A (en) 2014-05-30
TWI562987B (en) 2016-12-21

Similar Documents

Publication Publication Date Title
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
WO2012009009A3 (fr) Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EA201190139A1 (ru) Производные тиенопиримидиндиона в качестве модуляторов trpa1
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
ATE469144T1 (de) Substituierte pyridonverbindungen und anwendungsverfahren
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
WO2011006935A3 (fr) Dérivés de tétrazole
WO2009025785A3 (fr) Ligands de récepteur cb2 pour le traitement de la douleur
EA201190004A1 (ru) Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
GEP20135806B (en) Lactams as beta secretase inhibitors
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний
MA32479B1 (fr) Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques